NASDAQ:PTIX Protagenic Therapeutics (PTIX) Stock Price, News & Analysis $0.62 +0.05 (+8.77%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Protagenic Therapeutics alerts: Email Address About Protagenic Therapeutics Stock (NASDAQ:PTIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTIX alerts:Sign Up Key Stats Today's Range$0.57▼$0.6250-Day Range$0.53▼$1.0352-Week Range$0.50▼$1.89Volume8,699 shsAverage Volume88,186 shsMarket Capitalization$2.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Protagenic Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks14th Percentile Overall ScorePTIX MarketRank™: Protagenic Therapeutics scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Protagenic Therapeutics.Read more about Protagenic Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagenic Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagenic Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagenic Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Protagenic Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.80% of the float of Protagenic Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagenic Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagenic Therapeutics has recently increased by 3,669.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagenic Therapeutics does not currently pay a dividend.Dividend GrowthProtagenic Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.80% of the float of Protagenic Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagenic Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagenic Therapeutics has recently increased by 3,669.00%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.66 News SentimentProtagenic Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Protagenic Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for PTIX on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protagenic Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders37.00% of the stock of Protagenic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.97% of the stock of Protagenic Therapeutics is held by institutions.Read more about Protagenic Therapeutics' insider trading history. Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTIX Stock News HeadlinesShort Interest in Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Expands By 3,669.0%September 25 at 3:37 PM | americanbankingnews.comProtagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric DisordersMay 22, 2024 | finance.yahoo.comRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...September 28, 2024 | Behind the Markets (Ad)Protagenic Therapeutics, Inc.: Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston SummitApril 17, 2024 | finanznachrichten.deProtagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston SummitApril 17, 2024 | finance.yahoo.comProtagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call TranscriptApril 2, 2024 | msn.comProtagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric DisordersMarch 27, 2024 | finance.yahoo.comProtagenic Therapeutics, Inc.: Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings CallMarch 25, 2024 | finanznachrichten.deSee More Headlines PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed this year? Protagenic Therapeutics' stock was trading at $0.99 at the beginning of the year. Since then, PTIX stock has decreased by 37.4% and is now trading at $0.6199. View the best growth stocks for 2024 here. How were Protagenic Therapeutics' earnings last quarter? Protagenic Therapeutics, Inc. (NASDAQ:PTIX) posted its earnings results on Wednesday, August, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter. How do I buy shares of Protagenic Therapeutics? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today9/28/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTIX CUSIPN/A CIK1022899 Webwww.protagenic.com Phone212-994-8200Fax603-761-6223Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-238.38% Return on Assets-185.60% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.75Miscellaneous Outstanding Shares4,452,000Free Float2,805,000Market Cap$2.76 million OptionableNot Optionable Beta0.26 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:PTIX) was last updated on 9/28/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Hua...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.